(veracyte. Q1 2022 Business & Financial Presentation May 3, 2022 Disclaimer This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas and Decipher Bladder tests and prod ...

Veracyte, Inc. (NASDAQ:VCYT) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Giulia Kennedy – Chief Scientific & Medical Officer Tina Nova – General Manager of Thyroid & Urologic Cancer Sheila Goldman – Director of Investor Relations Conference Call Participants Brian Weinstein – William Blair David Hein – Goldman Sachs Mason Carrico – Stephens Inc. Tejas Savant – Morgan Stanley Paul Knight – KeyBa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of (I ...

veracyte. Q4 and Full Year 2021 Business & Financial Presentation February 28, 2022 Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, our statements related to our expected total revenue and other financial and operating results for 2022 and our plans, objectives, expectations (financial and otherwise) or intentions with respect to our Prosigna, Afirma, Percepta, Envisia, LymphMark, Decipher Prostate, Percepta Nasal Swab, Percepta Genomic Atlas ...

Veracyte, Inc. (NASDAQ:VCYT) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Tracy Morris - VP of Corporate Communications & IR Marc Stapley - CEO Rebecca Chambers - CFO Tina Nova - General Manager of Thyroid & Urologic Cancer Giulia Kennedy - Chief Scientific & Medical Officer Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Puneet Souda - SVB Leerink Mike Matson - Needham & Company Mason Carrico - Stephens Inc. Travis Broadhurst - L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission File Number 001-36156 VERACYTE, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 20-5455398 (I.R.S. Employer Identification Number) Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSU ...

veracyte. Third Quarter 2021 Performance Business & Financial Presentation November 9, 2021 Forward-Looking Statements This presentation contains statements that are not historical and that are based on our beliefs and assumptions and on information currently available to us. These statements constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks, uncerta ...

Call Start: 16:30 January 1, 0000 5:23 PM ET Veracyte, Inc. (NASDAQ:VCYT) Q3 2021 Earnings Conference Call November 9, 2021 16:30 ET Company Participants Tracy Morris - Vice President of Corporate Communications & Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Tina Nova - General Manager of Thyroid & Urologic Cancer Giulia Kennedy - Chief Scientific & Medical Officer Conference Call Participants Puneet Souda - SVB Leerink Matt Sykes - Goldman Sachs Mike ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36156 VERACYTE, INC. (Exact name of registrant as specified in its charter) Delaware 20-5455398 (State or ...

(veracyte. Second Quarter 2021 Performance July 29, 2021 Forward-Looking Statements This presentation contains statements that are not historical and that are based on our beliefs and assumptions and on information currently available to us. These statements constitute forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other fact ...